Finally, we show that a small molecule inhibitor of HIF-1α, PX-478, can impair the growth of KSHV-positive cells at concentrations that have little or no effect on KSHV-negative cells, suggesting that suppression of HIF-1 may be worth exploring as a therapy for PEL. Here, HIF1A is linked to primary effusion lymphoma.